Clinical Center; Notice of Meeting, 45253-45254 [07-3923]
Download as PDF
<![CDATA[
Federal Register / Vol. 72, No. 155 / Monday, August 13, 2007 / Notices
jlentini on PROD1PC65 with NOTICES
more efficiently than current available
technologies.
3. The average coverage of Agilent
oligoarray is 1 per 35kb of human
genome, while the average coverage of
the currently described technology is 1
per 400bp.
Developmental Status: The
technology is ready for use.
Benefits: More than 600,000 cancer
deaths are estimated to occur in 2007.
Efficient diagnosis and informed
decision making will aid in improved
clinical management of cancer. This
technology can rapidly diagnose cancer
and thus help in proper clinical
management leading to improved
overall survival and quality of life of
patients suffering from cancer. The
current in-vitro diagnostics market is
valued at $30 billion dollars and
expected to grow.
Inventors: Xiaolin Wu, David Munroe,
Ester Rozenblum, Hongling Liao (NCI/
SAIC).
Patent Status: U.S. Provisional
Application No. 60/911,411 filed 12
April 2007 (HHS Reference No. E–122–
2007/0–US–01).
Licensing Contact: Thomas P. Clouse,
J.D.; 301/435–4076;
clouset@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute
Laboratory of Molecular Technology is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate, or commercialize
CGH microarrays. Please contact John D.
Hewes, PhD at 301–435–3121 or
hewesj@mail.nih.gov for more
information.
Methods and Compositions for Treating
Diseases and Disorders Associated with
Natural Killer T–Cells
Description of Technology: The
invention relates to the discovery that
C12 beta-D-galactosyl ceramide may be
used to deplete or inactivate NKT cell
populations. These findings suggest
methods for using C12 beta-D-galactosyl
ceramide to treat conditions that would
benefit from depletion of NKT cells,
such as certain autoimmune diseases
(e.g. lupus, MS) and AIDS.
The presence of NKT cells can be
associated with either beneficial effects
or pathology. Deficiencies in NKT cells
are associated with at least some types
of autoimmune disease, including type
1 diabetes and autoimmune gastritis in
mice. In contrast, NKT cells augment
autoantibody secretion and lupus
development in lupus-prone mouse
models and therefore lupus patients
may benefit from the depletion of NKT
cells. The remission state of multiple
VerDate Aug<31>2005
16:19 Aug 10, 2007
Jkt 211001
sclerosis (MS) is also associated with
decreased levels of NKT cells,
suggesting NKT cell depletion as a
method of treatment for MS.
Inventors: John R. Ortaldo and Robert
H. Wiltrout (NCI).
Patent Status:
U.S. Provisional Application No. 60/
488,339 filed 17 July 2003 (HHS
Reference No. E–282–2002/0–US–01).
PCT Application No. PCT/US2004/
22913 filed 16 Jul 2004, which
published as WO 2005/014008 on 17
Feb 2005 (HHS Reference No. E–282–
2002/0–PCT–02).
European Application No. 04778424.4
filed 16 Jul 2004, which published as
1653977 on 10 May 2006 (HHS
Reference No. E–282–2002/0–EP–03).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Jennifer Wong;
301/435–4633; wongje@mail.nih.gov.
P53 and VGEF Regulate Tumor Growth
of NO2 Expressing Cancer Cells
Description of Technology: The
increased expression of nitric oxide
synthase 2 (NOS2), an inducible enzyme
that produces nitric oxide (NO), has
been found in a variety of human
cancers. It also has been shown that
NOS2-specific inhibitors can reduce the
growth of experimental tumors in mice.
These findings suggest a
pathophysiological role for NO in the
development and progression of cancer.
However, the function of NO and NOS2
in carcinogenesis is uncertain. NO had
been found to either inhibit or stimulate
tumor growth, and high concentrations
of NO also are known to induce cell
death in many cell types including
tumor cells. On the other hand, the
lower concentrations of NO that are
found in human tissue can have an
opposite effect and protect against
programmed cell death, or apoptosis,
from various stimuli. The role of NO
and NOS2 in tumor progression,
particularly with respect to p53,
therefore need to be further defined.
This invention comprises methods of
screening for modulators of NOS2
expression in p53 mutant cells, both in
vivo and in vitro, as well as methods for
predicting the chemotherapeutic benefit
of administering NOS2-inhibitors to
cancer patients. It has been
demonstrated that NOS2-expressing
cancer cells with wild-type p53 have
reduced tumor growth in athymic nude
mice whereas NOS2-expressing cancer
cells with mutated p53 have accelerated
tumor growth. Therefore, this invention
has potential application for a number
of cancers that overexpress NOS2 and
have a high frequency of p53 mutations,
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
45253
including breast, brain, head, neck, lung
and colon cancers.
Applications:
1. Method to treat cancer with NOS2
inhibitors.
2. Method to screen for NOS2
modulators.
3. Method to predict therapeutic
benefits of NOS2 inhibitors in patients.
Market:
1. An estimated 1,444,920 new cancer
diagnoses in the U.S. in 2007.
2. 600,000 deaths caused by cancer in
the U.S. in 2006.
3. Cancer is the second leading cause
of death in United States.
4. It is estimated that market for
cancer drugs would double to $50
billion a year in 2010 from $25 billion
in 2006.
Development Status: The technology
is currently in the pre-clinical stage of
development.
Inventors: Stefan Ambs and Curt
Harris (NCI).
Publications:
1. JE Goodman et al. Nitric oxide and
p53 in cancer-prone chronic
inflammation and oxyradical overload
diseases. Environ Mol Mutagen.
2004;44(1):3–9.
2. LJ Hofseth et al. Nitric oxide in
cancer and chemoprevention. Free
Radic Biol Med. 2003Apr 15;34(8):955–
968.
Patent Status:
U.S. Patent Application No. 11/
195,006 filed 01 Aug 2005 (HHS
Reference No. E–223–1998/0–US–04).
U.S. Patent Application No. 09/
830,977 filed 02 May 2001 (HHS
Reference No. E–223–1998/0–US–03).
PCT Patent Application No. PCT/
US1999/27410 filed 17 Nov 1998 (HHS
Reference No. E–223–1998/0–PCT–02).
U.S. Provisional Patent Application
No. 60/109,563 filed 23 Nov 1998 (HHS
Reference No. E–223–1998/0–US–01).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Jennifer Wong;
301/435–4633; wongje@mail.nih.gov.
Dated: August 3, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E7–15749 Filed 8–10–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Clinical Center; Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
E:\FR\FM\13AUN1.SGM
13AUN1
45254
Federal Register / Vol. 72, No. 155 / Monday, August 13, 2007 / Notices
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the NIH
Advisory Board for Clinical Research.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the contact person listed below in
advance of the meeting.
This meeting will be closed to the
public in accordance with provisions set
forth in section 552b(c)(6), Title 5
U.S.C., as amended to discuss personnel
matters, the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy. This
meeting is partially closed to the public.
jlentini on PROD1PC65 with NOTICES
Name of Committee: NIH Advisory Board
for Clinical Research.
Date: September 21, 2007.
Open: 10 a.m. to 1 p.m.
Agenda: To review the Clinical Center’s
operating plan and provide updates on
selected organizational initiatives.
Place: National Institutes of Health,
Building 10, 10 Center Drive, CRC Medical
Board, Room 4-2551, Bethesda, MD 20892.
Closed: 1 p.m. to 2 p.m.
Agenda: To review and evaluate personnel
matters.
Place: National Institutes of Health,
Building 10, 10 Center Drive, CRC Medical
Board, Room 4–2551, Bethesda, MD 20892.
Contact Person: Maureen E. Gormley,
Executive Secretary, Mark O. Hatfield
Clinical Research Center, National Institutes
of Health, Building 10, Room 6–2551,
Bethesda, MD 20892, (301) 496–2897.
Any interested person may file written
comments with the committee by forwarding
the statement to the contact person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Dated: August 6, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–3923 Filed 8–10–07; 8:45 am]
BILLING CODE 4140–01–M
VerDate Aug<31>2005
16:19 Aug 10, 2007
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Alcohol Abuse
and Alcoholism; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Alcohol Abuse and Alcoholism Special
Emphasis Panel, Neuroscience and Alcohol.
Date: October 2, 2007.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Beata Buzas, PhD,
Scientific Review Administrator, National
Institutes on Alcohol Abuse and Alcoholism,
National Institutes of Health, 5635 Fishers
Lane, Rm 3041, Rockville, MD 20852, 301–
443–0800. bbuzas@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.271, Alcohol Research
Career Development Awards for Scientists
and Clinicians; 93.272, Alcohol National
Research Service Awards for Research
Training; 93.273, Alcohol Research Programs;
93.891, Alcohol Research Center Grants,
National Institutes of Health, HHS)
Dated: August 7, 2007.
Toian Vaughn,
Committee Management Officer, Substance
Abuse and Mental Health Services
Administration.
[FR Doc. E7–15791 Filed 8–10–07; 8:45 am]
BILLING CODE 4162–20–P
Dated: August 6, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–3924 Filed 8–10–07; 8:45am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4140–01–M
Center for Substance Abuse
Prevention; Notice of Meeting
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Pursuant to Public Law 92–463,
notice is hereby given that the
Substance Abuse and Mental Health
Administration (SAMHSA) Center for
Substance Abuse Prevention (CSAP)
National Advisory Council (NAC) will
meet on August 28, 2007.
The meeting is open and will include
discussion of the Center’s policy issues
and current administrative, legislative,
and program developments.
Substance Abuse and Mental Health
Services Administration
Center for Mental Health Services;
Notice of Meeting
Pursuant to Public Law 92–463,
notice is hereby given that the
Substance Abuse and Mental Health
Jkt 211001
Services Administration (SAMHSA)
Center for Mental Health Services
(CMHS) National Advisory Council will
meet on August 14, 2007 from 2 p.m. to
3 p.m. via teleconference.
The meeting will include the review,
discussion and evaluation of grant
applications. Therefore the meeting will
be closed to the public as determined by
the Administrator, SAMHSA, in
accordance with Title 5 U.S.C.
552b(c)(6) and 5 U.S.C. App. 2, Section
10(d).
Substantive program information, a
summary of the meeting and a roster of
Council members may be obtained as
soon as possible after the meeting, either
by accessing the SAMHSA Committee
Web site at https://www.nac.samhsa.gov,
or by contacting the CMHS National
Advisory Council Executive Secretary,
Dianne McSwain (see contact
information below).
Committee Name: Substance Abuse
and Mental Health Services
Administration, Center for Mental
Health Services National Advisory
Council.
Date/Time/Type: August 14, 2007,
from 2 p.m. to 3 p.m.: Closed.
Place: 1 Choke Cherry Road,
Conference Room 6–1060, Rockville,
Maryland 20852.
Contact: Dianne McSwain, M.S.W.,
Executive Secretary, SAMHSA CMHS
National Advisory Council, 1 Choke
Cherry Rd., Rm. 6–1063, Rockville,
Maryland 20857, Telephone: (240) 276–
1828, E-mail:
dianne.mcswain@samhsa.hhs.gov.
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
Substance Abuse and Mental Health
Services Administration
E:\FR\FM\13AUN1.SGM
13AUN1
]]>Agencies
[Federal Register Volume 72, Number 155 (Monday, August 13, 2007)]
[Notices]
[Pages 45253-45254]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-3923]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Clinical Center; Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
[[Page 45254]]
amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of
the NIH Advisory Board for Clinical Research.
The meeting will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need special assistance, such as sign language interpretation or
other reasonable accommodations, should notify the contact person
listed below in advance of the meeting.
This meeting will be closed to the public in accordance with
provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended
to discuss personnel matters, the disclosure of which would constitute
a clearly unwarranted invasion of personal privacy. This meeting is
partially closed to the public.
Name of Committee: NIH Advisory Board for Clinical Research.
Date: September 21, 2007.
Open: 10 a.m. to 1 p.m.
Agenda: To review the Clinical Center's operating plan and
provide updates on selected organizational initiatives.
Place: National Institutes of Health, Building 10, 10 Center
Drive, CRC Medical Board, Room 4-2551, Bethesda, MD 20892.
Closed: 1 p.m. to 2 p.m.
Agenda: To review and evaluate personnel matters.
Place: National Institutes of Health, Building 10, 10 Center
Drive, CRC Medical Board, Room 4-2551, Bethesda, MD 20892.
Contact Person: Maureen E. Gormley, Executive Secretary, Mark O.
Hatfield Clinical Research Center, National Institutes of Health,
Building 10, Room 6-2551, Bethesda, MD 20892, (301) 496-2897.
Any interested person may file written comments with the
committee by forwarding the statement to the contact person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one
form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their
visit.
Dated: August 6, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 07-3923 Filed 8-10-07; 8:45 am]
BILLING CODE 4140-01-M
